Lead Sponsor

Pfizer

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

•Developed at least one COVID-19 symptom between Apr 1, 2022 through Dec 31, 2023
•A positive lab-confirmed polymerase chain reaction (PCR) SARS-COV-2 test 5 days after symptom onset (primary analysis).
•Continuous enrollment in KPSC health plans for at least 1 year (allowing for a 31-day gap to account for potential delays in membership renewal) before the date of symptom onset
•Active membership in KPSC health plans for at least 31 days after the date of symptom onset
•Eligible for nirmatrelvir-ritonavir defined by age and CDC-defined risk factors for severe COVID-19

•Individuals on another medication that is contraindicated for treatment with nirmatrelvir-ritonavir defined as having any prescription drug claim in the 90 days prior to COVID-19 symptom onset
•Receipt of any COVID-19 antiviral (molnupiravir, remdesivir, nirmatrelvir/ritonavir) or monoclonal antibody treatment (bamlanivimab, bebtelovimab, casirivimab/imdevimab, cilgavimab/tixagevimab, otrovimab,) \<180 days prior to COVID-19 symptom onset
•Any positive SARS-CoV-2 test, including self-reported tests, \<180 days prior to COVID-19 symptom onset.

Related studies

NCT06631287 · Long COVID, Sars-CoV-2 Infection, and more

NCT05101213 · Adenovirus Infection, BK Virus Infection, and more

NCT04565665 · COVID-19 Infection, COVID-19-Associated Acute Respiratory Distress Syndrome, and more

NCT06871293 · Long COVID-19 Syndrome, COVID 19, and more

NCT06095297 · Long COVID, Brain Fog, and more

A Study to Understand How the Use of Paxlovid Affected Healthcare Use in People With Pre-existing Conditions.